[A case of advanced breast cancer associated with humoral hypercalcemia that responded to medroxyprogesterone acetate and docetaxel].
A 67-year-old woman with a left advanced breast cancer was admitted to our hospital. Chest CT revealed a parasternal lymph nodal metastasis invading into the sternum, an axillary lymph nodal metastasis, and a lung metastasis. The clinical stage of the patient was i.v. (T4bN2M1). Laboratory examination showed humoral hypercalcemia. After controlling the hypercalcemia with alendronate, sodium hydrate she received chemoendocrine therapy with medroxyprogesterone acetate (MPA) (800 mg/day) and docetaxel (60 mg/body once every three weeks). A complete response was obtained in the primary and metastatic lesions after 3 cycles of docetaxel. This case suggests the efficacy of the combined therapy with MPA and docetaxel on advanced breast cancers.
Kunisue
H
H
Dept. of Breast and Thyroid Surgery, Kawasaki Medical School.
Kurebayashi
J
J
Sonoo
H
H
Udagawa
K
K
Yamamoto
Y
Y
Yamamoto
S
S
Tanaka
K
K
Shimozuma
K
K
D000284:Administration, Oral; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001365:Axilla; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000150:complications*; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage; D009361:Neoplasm Invasiveness; D017239:Paclitaxel / Q000008:administration & dosage / Q000031:analogs & derivatives; D043823:Taxoids
D043823:Taxoids; D000077143:Docetaxel; D017258:Medroxyprogesterone Acetate; D017239:Paclitaxel